Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study
Jiajun Liu, Steven YC Tong, Joshua S Davis, Nathaniel J Rhodes, Marc H Scheetz
Open Forum Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2020
Among patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia from a prospective randomized clinical trial, acute kidney injury (AKI) rates increased with increasing vancomycin exposure, even within the therapeutic range. AKI was independently more common for the (flu)cloxacillin group. Day 2 vancomycin AUC ≥470 mg·h/L was significantly associated with AKI, independent of (flu)cloxacillin receipt.
Awarded by National Institute of Allergy and Infectious Diseases
The research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases under award number R21AI149026 (to M. H. S.). S. Y. C. T. (1145033) and J. S. D. (1160331) are supported by Australian National Health & Medical Research Council Career Development Fellowships.